Source comparison
Tesamorelin vs Sermorelin vs CJC-1295: GHRH Analogue Comparison
Tesamorelin 26–38 minutes VAT reduction in HIV lipodystrophy High. 15–20% reduction in clinical trials FDA-approved (Egrifta) Only GHRH analogue with proven VAT reduction efficacy; short half-life requires daily dosing Sermorelin 8–12 minutes General GH stimul
This comparison does not assign a generated winner or score.
- Tesamorelin
- 26–38 minutes
- VAT reduction in HIV lipodystrophy
- High. 15–20% reduction in clinical trials
- FDA-approved (Egrifta)
- Only GHRH analogue with proven VAT reduction efficacy; short half-life requires daily dosing
- Sermorelin
- 8–12 minutes
- General GH stimulation, anti-aging
- Moderate. Non-selective lipolysis
- Not FDA-approved for therapeutic use
- Shortest half-life of the three; limited clinical data on fat loss endpoints
- CJC-1295 (DAC)
- 6–8 days
- Sustained GH elevation
- Low. Chronic elevation reduces pulsatility
- Not FDA-approved
- Extended half-life creates continuous GH elevation, which may impair insulin sensitivity over time
- Tesamorelin stands apart in selectivity. While sermorelin and CJC-1295 both stimulate GH release, neither has demonstrated the same degree of visceral fat reduction in controlled trials. Sermorelin's ultra-short half-life (8–12 minutes) limits its clinical utility. The GH pulse is too brief to generate sustained IGF-1 elevation. CJC-1295 with DAC (Drug Affinity Complex) extends half-life to 6–8 days, creating near-constant GH elevation. That sounds beneficial until you examine the metabolic consequences: chronic GH exposure desensitizes GH receptors, impairs glucose tolerance, and increases water retention.
- What tesamorelin actually does is occupy the middle ground. Long enough to trigger meaningful IGF-1 synthesis, short enough to preserve feedback regulation. The 26–38 minute half-life allows daily pulsatile dosing without receptor desensitization. This is why tesamorelin earned FDA approval for lipodystrophy while other GHRH analogues remain research compounds. The clinical endpoint data exists for tesamorelin; for sermorelin and CJC-1295, most evidence is anecdotal or extrapolated from small Phase I/II trials.